Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04689594
Recruitment Status : Recruiting
First Posted : December 30, 2020
Last Update Posted : December 30, 2020
Sponsor:
Information provided by (Responsible Party):
CellSeed Inc.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of esophageal epithelial regenerative treatment by the transplantation of the product, CLS2702C, to the esophageal wound site after extensive ESD for superficial esophageal cancer in the steroid administration risk group.

Condition or disease Intervention/treatment Phase
Superficial Esophageal Cancer Combination Product: CLS2702C/CLS2702D Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 17 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase III, Multicenter, Open-label Study to Evaluate the Esophageal Stenosis Inhibition Effects and Safety of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
Estimated Study Start Date : February 4, 2021
Estimated Primary Completion Date : July 31, 2025
Estimated Study Completion Date : August 31, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CLS2702C/CLS2702D Combination Product: CLS2702C/CLS2702D

CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month [4 weeks]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months [24 weeks]); follow-up period, 6 months [24 weeks]) Other Names: •Human (autologous) oral mucosal cell sheet

•Transplantation device





Primary Outcome Measures :
  1. Proportion of subjects without stenosis [ Time Frame: 24 weeks after endoscopic ]
    Proportion of participants without stenosis until 24 weeks after endoscopic submucosal dissection (ESD)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who plan to undergo ESD for the treatment of superficial esophageal cancer
  2. Patients aged >=20 years at the time of consent
  3. Patients with no clinical metastasis (cN0M0) by cervical to abdominal CT
  4. Patients with an endoscopically diagnosed depth of wall invasion remaining in the epithelium (EP) or lamina propria mucosae (LPM)
  5. Patients with a tumor diagnosed as >=50% and <100% of circumference, and with prediction that resection circumference will be >=75% and <100%.
  6. Patients with a tumor the major axis is <=50 mm, and with prediction that a major axis of a resection will be <=80 mm.
  7. If the patient has multiple lesions, the circumference of all minor lesions other than the one lesion with the largest circumference (major lesion) must be <50%. However, if it is predicted that the major axis of the mucosal defect is >80 mm due to treating the major and minor lesions and assembling ulcers after the treating, the patient is excluded.
  8. Patients with squamous cell carcinoma (including high-grade intraepithelial neoplasia) as confirmed by biopsy
  9. Patients whose lesion is confirmed to be localized in the thoracic esophagus (lesions in the cervical esophagus or abdominal esophagus will be excluded). The location of the lesion will be determined by endoscopy.
  10. Patients who have not received pretreatment for esophageal cancer. Treatment by ESD for superficial esophageal cancer for which the depth of wall invasion has been assessed to remain in the epithelium (EP) or lamina propria mucosae (LPM) is not included in the definition of pretreatment. However, patients who have a scar due to previous ESD in the major or minor lesions will be excluded from the study.
  11. Patients with an ECOG Performance Status (PS) of 0 or 1
  12. Patients in whom a commonly used endoscope with a tip diameter of 8.9 mm can pass
  13. Patients with a dysphagia score of 0
  14. Patients whose laboratory values within 28 days before enrolment meet all of the following criteria:

    • White blood cell count: >=4,000/microL
    • Platelet count: >=100,000/microL
    • AST: <=100 IU/L
    • ALT: <=100 IU/L
    • Total bilirubin: <=2.0 mg/dL
    • Serum creatinine: <=2.0 mg/dL
  15. Patients who have received sufficient explanation about the study and provided written voluntary consent.
  16. Patients who meet any of the following criteria:

    • With fibrous nodule shadow on IGRA negative diagnostic imaging
    • Required continuous systemic administration of immunosuppressants
    • With diabetes with blood glucose level of 180 mg/dL or more 2 hours after meal even with insulin
    • With 7.0% or more of hemoglobin A1c (HbA1c, (International standard value (NGSP value)) even if taking 2 or more drug treatments for more than 3 months
    • With high blood pressure which does not reach the target value even if taking 2-3 antihypertensive drugs or reach it with 4 or more antihypertensive drugs
    • With glaucoma, posterior capsule cataract or herpes simplex keratitis (Ophthalmology consultation is not mandatory)
    • With a risk of administration of corticosteroids based on medical judgment.

Exclusion Criteria:

  1. Patients with cardiac disease (myocardial infarction, unstable angina, and heart failure), renal disease (nephrotic syndrome and kidney failure)
  2. Patients who have an active (within 1 year) malignancy other than esophageal cancer
  3. Patients with active bacterial, fungal, or viral infection
  4. Patients who are being treated with a corticosteroid except for topical corticosteroids (ointments and creams) and oral ointments or patches used for treating stomatitis after oral mucosal tissue taken from D-16 to D-1.
  5. Patients who are positive for any of serological test (HBs antigen, HBc antibody/HBs antibody, HCV antibody, HIV-1/2 antibody, HTLV-1 antibody, syphilis treponema antibody) or nucleic acid amplification test (HBV-DNA, HCV-RNA, HIV-RNA). However, this does not apply if the HBs antibody is positive and HBV-DNA is negative and the reason is clear that he was vaccinated with the hepatitis B vaccine.
  6. Patients with a mental disorder that is difficult to control
  7. Pregnant women, lactating women, and potentially pregnant women
  8. Patients who have participated in another clinical study within 6 months, those who are participating in another clinical study, and those who plan to participate in another clinical study during participation in this study
  9. Patients from whom tissues cannot be collected due to a disease (e.g., stomatitis, erosion, mass, and blister) in the oral mucosa at the tissue collection site
  10. Patients with a history of hypersensitivity to antibiotic preparations (ampicillin sodium, sulbactam sodium, streptomycin sulfate, gentamicin sulfate, or amphotericin B) or who have taken drugs that may affect the study (within 28 days before enrolment)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04689594


Contacts
Layout table for location contacts
Contact: Yuki Saito +818047383926 yuki.saito@cellseed.com

Locations
Layout table for location information
Japan
Okayama University Hospital Recruiting
Okayama, Japan, 700-8558
Contact: Yuki Saito    +818047383926    yuki.saito@cellseed.com   
Sponsors and Collaborators
CellSeed Inc.
Layout table for additonal information
Responsible Party: CellSeed Inc.
ClinicalTrials.gov Identifier: NCT04689594    
Other Study ID Numbers: CLS2702-ESO-02
First Posted: December 30, 2020    Key Record Dates
Last Update Posted: December 30, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Esophageal Stenosis
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases